OPTIMAL-DIABETES Trial at AHA Scientific Sessions in Chicago, Illinois: Intensive Blood Pressure Target Below 120 Did Not Significantly Cut Cardiovascular Events in 9,476 Adults With Type 2 Diabetes, 6% Versus 6.7%
CHICAGO, Cook County, Illinois — Results of the OPTIMAL-DIABETES trial, presented on November 7 at the American Heart Association's Scientific Sessions 2026 in Chicago, showed that intensive blood pressure lowering to a systolic target below 120 mm Hg, compared with standard treatment targeting below 140 mm Hg, did not significantly reduce cardiovascular death, stroke, heart attack and other cardiovascular events in adults with type 2 diabetes at increased cardiovascular risk. The results were published simultaneously as a full manuscript in the New England Journal of Medicine.
According to the American College of Cardiology's meeting coverage, the trial randomly assigned 9,476 adults aged 50 and older — average age 65 — at 33 sites in Brazil. Participants had systolic blood pressure between 130 and 180 mm Hg, type 2 diabetes and additional cardiovascular risk factors; they were enrolled from August 2019 to October 2021 and followed for a median of four years. The primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina or heart failure occurred in 6% of the intensive group versus 6.7% of the standard group, a difference that was not statistically significant. The researchers also reported that mean systolic blood pressure, excluding the first three months, was lower in the intensive group.
The lead study author was Karla Santo, M.D., Ph.D., of the Academic Research Organization of Einstein Hospital Israelita in S?o Paulo, Brazil. Investigator Otavio Berwanger, M.D., Ph.D., said the findings should not be interpreted as evidence that more intensive blood pressure lowering is ineffective for people with type 2 diabetes, but rather suggest that any cardiovascular benefit may be smaller than in individuals without diabetes, so that even a large trial may not definitively detect a modest effect. This report presents only the published trial data and the investigators' statements and does not constitute medical advice for any individual.
来源链接：美国心脏病学会会议报道（acc.org）： https://www.acc.org/latest-in-cardiology/articles/2026/11/06/14/37/sat-5pm-yoga-aha-2026
Source: American Heart Association
Published by GSM · USA (original Chinese edition)
Photo: 图：血压测量。https://www.myupchar.com/en 摄，CC BY-SA 4.0，经 Wikimedia Commons。 / Photo: Blood pressure measurement. Photo by https://www.myupchar.com/en, CC BY-SA 4.0, via Wikimedia Commons.
Yoga-CaRe Heart Failure Trial in Chicago, Illinois: 3,492 Patients Gained 8.1 Quality-of-Life Points and 25.5 Metres on the Six-Minute Walk at Three Months, With No Significant Difference in Death, Hospitalization or Stroke at 21.0% Versus 22.8%2026-11-08
At the AHA Sessions in Chicago, Illinois, a November 8 Poster on Evategrel: Chinese and U.S. Participants Showed Comparable Pharmacokinetics and Pharmacodynamics, and Food Slowed Absorption but Not Total Exposure2026-11-08